Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aviragen Comments on ISS Report
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen
View HTML
Toggle Summary Aviragen Therapeutics Issues Letter to Stockholders
Reiterates Benefits of Proposed Merger with Vaxart   Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA , Jan. 24, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued a letter to stockholders urging them to vote FOR
View HTML
Toggle Summary Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
ATLANTA , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4
View HTML
Toggle Summary Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results
ATLANTA , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. "Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive
View HTML
Toggle Summary Aviragen Therapeutics and Vaxart Enter into Merger Agreement
  Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics  Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET  ATLANTA and SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.
View HTML
Toggle Summary Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study
Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study  
View HTML
Toggle Summary Aviragen Therapeutics and Vaxart Enter into Merger Agreement View HTML
Toggle Summary Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study View HTML
Toggle Summary Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
ATLANTA , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017. "We have made great strides, working with our Board and financial advisors, in honing in on a select number of
View HTML
Toggle Summary Vaxart to Present at the Jefferies 2017 Healthcare Conference View HTML
Toggle Summary Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results
ATLANTA , May 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. "We are expeditiously working with our Board and financial
View HTML
Toggle Summary Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
ATLANTA , April 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced that based on a review of the
View HTML
Toggle Summary Vaxart Announces Positive Phase 1 Study of Oral Norovirus Vaccine View HTML
Toggle Summary Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
ATLANTA , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS
View HTML

Log In

Create an account